



Neurotech successfully completes \$4m placement

- *Well oversubscribed placement to institutional & sophisticated investors*
- *Funds raised at \$0.20, a 7% discount to last traded price*
- *Capital to provide platform for manufacturing & acquiring additional inventory, further product enhancements, pursuit of strategic opportunities & working capital*

Perth, Australia & Malta – 16 October 2017 – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions in the neuroscience space, has successfully completed a well oversubscribed A\$4 million placement of new shares to drive the Company’s ongoing commercialisation of the Mente Autism device.

The placement of 20 million ordinary new shares in the Company was conducted at \$0.20 per share, a 7% discount to the last traded price of \$0.215 per share and 10.5% discount to the five-day VWAP of \$0.223 as at 10 October 2017.

The capital raising will be conducted under two tranches:

Tranche 1 – comprising 13,205,266 shares, raising \$2.641 million under the Company’s existing ASX Listing Rule 7.1 capacity; and

Tranche 2 – comprising 6,794,734 shares, raising a further \$1.359 million subject to shareholder approval to be sought at the upcoming general meeting.

Settlement of Tranche 1 is expected on Friday 20 October, with approval and settlement of Tranche 2 expected in late November. These timings are subject to change.

The funds raised in the placement will be used for further product enhancements on Mente Autism, manufacturing and purchase of additional inventory, investigating potential strategic initiatives and general working capital.

Azure Capital Limited was sole lead manager to the equity raising.

Speaking on the placement, Neurotech CEO Wolfgang Storf said: “We are very pleased with the strong response to the placement of new shares from both new and existing investors in the company.

“We are entering what we expect to be a pivotal time for Neurotech and the Mente Autism device. This will include pursuit of further distributorships, completion of the trial as well as ongoing improvements to the Mente Autism device.”

“We thank all shareholders for their ongoing support and look forward to building upon this momentum moving forward.”

-ends-

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

For more information please contact:

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420